Janney Montgomery Scott LLC Has $29.80 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Janney Montgomery Scott LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 123,614 shares of the medical instruments supplier’s stock after acquiring an additional 472 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Becton, Dickinson and Company were worth $29,804,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company in the third quarter worth $26,000. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth $45,000. Abound Wealth Management grew its position in Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC grew its position in Becton, Dickinson and Company by 1,233.3% in the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

BDX stock opened at $234.33 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $259.92. The firm has a market cap of $67.73 billion, a P/E ratio of 48.22, a P/E/G ratio of 1.75 and a beta of 0.43. The company’s 50-day moving average price is $237.52 and its two-hundred day moving average price is $235.10.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BDX shares. Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Raymond James decreased their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.